Friday, October 02, 2020 9:10:06 AM
Note the obvious failure of the 3Q 10Q management commentary
"securing our first orders for recurring, volume, deliveries of functional parts utilizing our technology. Monthly shipments began in July and will result in regular supply into a targeted market".
Not one word or phrase was dedicated to REVENUE.
Every positive statement on this board about the commentary has not addressed this fact.
There is no description of how revenues were generated (by sales from US staff to their customer base or by royalty of sales made by Eontec to its customer base in US or Europe. NO DESCRIPTION of REVENUE.
You can say all you want about "first orders, recurring, volume, deliveries, etc.", but if you don't say anything about revenues...well, just how valuable is that information?
What if all revenue streams are minimized or even loss leaders just to secure the "first orders".
Professor Li has NEVER discussed REVENUES apart from rent or interest or dividend income from securities.
As far as I know, CHINA is begging for US dollars to keep its economy going...and, in my opinion, will keep as many US DOLLARS in CHINA. Surely, this is going to impact any revenue sharing agreement between Professor Li (Eontec) and Professor Li (LQMT).
This is what is scarry for me as an investor...we have nos assurance that LQMT will get any fair share of any revenue pie, because it is PRIMARY that EONTEC stay afloat...NOT LQMT.
Just sayin.
Time to brew my coffee so I can take my meds.
What with the markets extremely spooked due to the WUHAN VIRUS NEWS this morning, it is hard to make any prediction for today, but it surely is going to be a real bloodbath. For us, I would say at least ten percent to the downside.
Certainly, not the 20 cents forecast. We still are NOT EVEN THERE.
Recent LQMT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 10:15:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 10:26:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 08:41:42 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM